Catecholamines Regulate Tumor Angiogenesis

Among the regulators of angiogenesis, catecholamine neurotransmitters are of recent interest because of their opposite roles in the regulation of tumor neovascularization. Norepinephrine and epinephrine by acting through specific adrenoceptors increase the synthesis of proangiogenic factors, and the...

Full description

Saved in:

Bibliographic Details
Published in:	Cancer research (Chicago, Ill.) Ill.), 2009-05, Vol.69 (9), p.3727-3730
Main Authors:	CHAKROBORTY, Debanjan, SARKAR, Chandrani, BASU, Biswarup, SARATHI DASGUPTA, Partha, BASU, Sujit
Format:	Article
Language:	eng
Subjects:	Angiogenesis Inhibitors - pharmacology Angiogenic Proteins - antagonists & inhibitors Angiogenic Proteins - biosynthesis Angiogenic Proteins - metabolism Animals Antineoplastic agents Biological and medical sciences Catecholamines - metabolism Humans Medical sciences Neoplasms - blood supply Neoplasms - drug therapy Neoplasms - metabolism Neovascularization, Pathologic - drug therapy Neovascularization, Pathologic - metabolism Neovascularization, Pathologic - pathology Pharmacology. Drug treatments Tumors
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Among the regulators of angiogenesis, catecholamine neurotransmitters are of recent interest because of their opposite roles in the regulation of tumor neovascularization. Norepinephrine and epinephrine by acting through specific adrenoceptors increase the synthesis of proangiogenic factors, and thereby, promote tumor growth. In contrast, dopamine acting via its specific D(2) receptors inhibits tumor growth by suppressing the actions of vascular permeability factor/vascular endothelial growth factor-A on both tumor endothelial and bone marrow-derived endothelial progenitor cells. These reports identify novel endogenous regulators of tumor angiogenesis and also indicate a new and an inexpensive class of antiangiogenic drugs for the treatment of cancer.
ISSN:	0008-5472 1538-7445